產(chǎn)品詳情
  • 產(chǎn)品名稱:LysophosphatidicAcidReceptor3(LPAR3)Peptide

  • 產(chǎn)品型號(hào):
  • 產(chǎn)品廠商:KamiyaBiomedical
  • 產(chǎn)品文檔:
你添加了1件商品 查看購(gòu)物車
簡(jiǎn)單介紹:
LysophosphatidicAcidReceptor3(LPAR3)Peptide
詳情介紹:
Background EDG-7 belongs to a family of G-protein coupled receptors whose ligands are lysophospholipids. The ligand for EDG-7 is lysophospholipid. There are 8 known members of the EDG receptor family and they are implicated in mediating growth related effects such as induction of cellular proliferation, alterations in differentiation and survival and suppression of apoptosis. They also evoke cellular effector functions that are dependent on cytoskeletal responses such as contraction, secretion, adhesion, and chemotaxis. EDG receptors are developmentally regulated and differ in tissue distribution. They couple to multiple types of G proteins to signal through ras and MAP kinase, rho, phospholipase C, and several protein tyrosine kinases. EDG-7 is expressed in prostate as well as other tissues.
Application Notes For use with EDG-7 (CT) polyclonal antibody (ABIN187789). Incubate antibody neat with at least a 50 fold stoichiometric excess of blocking peptide at 37°C for 20 min (moluclar weights of peptide and antibody are 2.5 kDa and 160 kDa, respectively). Antibody can then be diluted to a concentration suitable for Western blot.
Restrictions For Research Use only
Format Liquid
Buffer Provided as 1 mg/ml in PBS.
Storage -20 °C